LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

VistaSeq GYN Cancer Panel

CPT:

Call client services

This assay is intended for patients with a family history consistent with an inherited cancer syndrome.

Test Details

Use

This assay is intended for patients with a family history consistent with an inherited cancer syndrome.

Synonyms

Familial Cancer testing, Hereditary Cancer testing, Inherited Cancer testing

Methodology

The entire coding region of a panel of genes related to hereditary cancer is examined by next generation sequencing analysis. Additionally, portions of the flanking noncoding regions are also examined. Comprehensive deletion/duplication testing is performed using microarray CGH for 9 genes, and by multiplex ligation-dependent probe amplification (MLPA) for the CHEK2 and PMS2 genes. Genes tested in this panel include BRCA1, BRCA2, CHEK2, EPCAM, MHL1, MSH2, MSH6, MUTYH, PMS2, PTEN and TP53. Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).

Specimen Requirements

Specimen

Whole blood

Volume

10 mL

Minimum Volume

7 mL

Container

Lavender-top (EDTA) tube or yellow-top (ACD) tube

Collection

Blood is collected by routine phlebotomy

Special Instructions

clinical questionnaire should be submitted with all specimens

Causes for Rejection

Frozen or hemolyzed specimen; quantity not sufficient for analysis

Storage Instructions

Room temperature

Additional Information

Limitations

This assay is not designed to detect deep intronic variants, balanced translocations, large inversions, mosaicism or complex genomic rearrangements. Homopolymer regions and rare polymorphisms under primer sites can affect the performance of the assay. The presence of pseudogenes can interfere with the ability to detect variants in certain genes. This assay is not intended for use in patients who have received allogeneic bone marrow transplants, as it may not reflect the germline genetic status of these patients.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

Patient?

Patient?

If you’re a healthcare provider, you’re in the right place. If you’re a current or future patient, click the link below.